466 results on '"Mayer, Erica L."'
Search Results
152. Phase II trial of pembrolizumab in patients with brain metastases.
153. Circulating tumor cells (CTCs) dynamics after CDK4/6i for hormone-receptor positive (HR+) metastatic breast cancer (MBC): A biomarker analysis of the PACE randomized phase II study.
154. Association of tumor infiltrating lymphocyte quantity with survival in patients (pts) with metastatic breast cancer (MBC) receiving microtubule-targeting agents: Post hoc analysis CALGB 40502 (Alliance).
155. Oncology Summary
156. Cardiovascular Health of Patients With Cancer and Cancer Survivors
157. Impact of the LIVESTRONG at the YMCA Program on physical activity, fitness, and quality of life in cancer survivors.
158. Abstract P3-06-11: Homologous recombination deficiency (HRD) assay predicts response to cisplatin neoadjuvant chemotherapy in patients with triple negative breast cancer
159. Breast Cancer Axillary Staging: Much Ado About Micrometastatic Disease
160. Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers
161. Staging Workup in Pregnant Cancer Patients.
162. Effect of the LIVESTRONG at the YMCA exercise program on physical activity, fitness, quality of life, and fatigue in cancer survivors.
163. Adjuvant palbociclib (P) plus endocrine therapy (ET) for hormone receptor positive (HR+) breast cancer: A phase II feasibility study.
164. Evaluating the utility of baseline cardiac function assessment in early-stage breast cancer treatment.
165. A phase II study of eribulin in patients with HER2-negative, metastatic breast cancer: Evaluation of efficacy, toxicity, and patient-reported outcomes.
166. TBCRC030: A randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC)—Evaluating the homologous recombination deficiency (HRD) biomarker.
167. Identification of biomarkers to predict response to single-agent platinum chemotherapy in metastatic triple-negative breast cancer (mTNBC): Correlative studies from TBCRC009.
168. Rosuvastatin Lowers Circulating Tissue Factor Antigen-Bearing Microparticles In Metastatic Breast Cancer: A Phase II, Multi-Dose, Randomized Trial (MicroSTAT Trial)
169. Adjuvant palbociclib for ER+ breast cancer (PALLAS Trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): A preplanned analysis of the stage IIA cohort.
170. Reply to V. Pitini et al
171. Phase II study of ruxolitinib in patients with pStat3+ breast cancer.
172. Sentinel lymph node biopsy (SNB) in pregnancy-associated breast cancer (PABC).
173. Immediate tissue expander breast reconstruction following mastectomy in pregnancy-associated breast cancer.
174. Prospective clinical experience with research biopsies in breast cancer patients.
175. Early and Late Long-Term Effects of Adjuvant Chemotherapy
176. Long Term Follow-Up of National Surgical Adjuvant Breast and Bowel Project Trial B-31: How Well Can We Predict Cardiac Toxicity With Trastuzumab?
177. TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
178. CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC).
179. Reply to E. Warner
180. Breast Cancer Survivors' Perceptions of Survivorship Care Options
181. A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer
182. Contrary Effects of the Receptor Tyrosine Kinase Inhibitor Vandetanib on Constitutive and Flow-Stimulated Nitric Oxide Elaboration in Humans
183. Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab
184. Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review
185. Advances in Targeting Src in the Treatment of Breast Cancer and Other Solid Malignancies
186. In Reply
187. Weighing a Dose-Dense Option for Adjuvant Chemotherapy and Trastuzumab in Early-Stage Breast Cancer
188. Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer
189. Chemotherapy for Metastatic Breast Cancer
190. Novel Approaches to Advanced Breast Cancer: Bevacizumab and Lapatinib
191. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB...
192. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.
193. Purification and Characterization of the Vaccinia Virus Deoxyuridine Triphosphatase Expressed in
194. Inhibition of Cyclin-Dependent Kinases 4 and 6 in Breast Cancer.
195. Cardiovascular Health of Patients With Cancer and Cancer Survivors A Roadmap to the Next Level
196. Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis.
197. Association of N-terminal pro–brain natriuretic peptide with survival among US cancer survivors.
198. Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131.
199. Follow-Up of Breast Cancer Survivors.
200. Clonal hematopoiesis in older patients with breast cancer receiving chemotherapy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.